Acelrx Pharmaceuticals Inc logo

ACRX

Acelrx Pharmaceuticals Inc

$0.31

Earnings Summary

Revenue
$0.44Mn
Net Profits
$-8.67Mn
Net Profit Margins
-1962.44%
PE Ratio
1.1

Highlights

Revenue:

Acelrx Pharmaceuticals Inc’s revenue fell -13.5% since last year same period to $0.44Mn in the Q1 2022. On a quarterly growth basis, Acelrx Pharmaceuticals Inc has generated 123.76% jump in its revenue since last 3-months.

Net Profits:

Acelrx Pharmaceuticals Inc’s net profit jumped 3.15% since last year same period to $-8.67Mn in the Q1 2022. On a quarterly growth basis, Acelrx Pharmaceuticals Inc has generated -9.56% fall in its net profits since last 3-months.

Net Profit Margins:

Acelrx Pharmaceuticals Inc’s net profit margin fell -11.97% since last year same period to -1962.44% in the Q1 2022. On a quarterly growth basis, Acelrx Pharmaceuticals Inc has generated -561.05% fall in its net profit margins since last 3-months.

PE Ratio:

Acelrx Pharmaceuticals Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 1.1.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Acelrx Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.07
EPS Estimate Current Year
-0.07

Highlights

EPS Estimate Current Quarter:

Acelrx Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.07 - a -16.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Acelrx Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.07.

Key Ratios

Key ratios of the Acelrx Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.06
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Acelrx Pharmaceuticals Inc’s earning per share (EPS) jumped 25% since last year same period to -0.06 in the Q1 2022. This indicates that the Acelrx Pharmaceuticals Inc has generated 25% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acelrx Pharmaceuticals Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acelrx Pharmaceuticals Inc’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Acelrx Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.06
-0.06
0%

Company Information

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.

Organisation
Acelrx Pharmaceuticals Inc
Headquarters
Redwood City, California, US
Employees
54
Industry
Health Technology
CEO
Vincent Angotti